JP2023529095A - 高用量低体積のボツリヌス毒素による顔のシワの治療 - Google Patents

高用量低体積のボツリヌス毒素による顔のシワの治療 Download PDF

Info

Publication number
JP2023529095A
JP2023529095A JP2022573504A JP2022573504A JP2023529095A JP 2023529095 A JP2023529095 A JP 2023529095A JP 2022573504 A JP2022573504 A JP 2022573504A JP 2022573504 A JP2022573504 A JP 2022573504A JP 2023529095 A JP2023529095 A JP 2023529095A
Authority
JP
Japan
Prior art keywords
wrinkles
botulinum toxin
dose
facial
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573504A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021245223A5 (https=
JP2023529095A5 (https=
Inventor
ロール ズザナ
スラーデク マイク
ガイスター トーリン
ピュルテ イレーナ
バイセンベルガー ペトラ
クライン グートルーン
Original Assignee
メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71016459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2023529095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー filed Critical メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー
Publication of JP2023529095A publication Critical patent/JP2023529095A/ja
Publication of JPWO2021245223A5 publication Critical patent/JPWO2021245223A5/ja
Publication of JP2023529095A5 publication Critical patent/JP2023529095A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022573504A 2020-06-05 2021-06-04 高用量低体積のボツリヌス毒素による顔のシワの治療 Pending JP2023529095A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20178574.8 2020-06-05
EP20178574 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Publications (3)

Publication Number Publication Date
JP2023529095A true JP2023529095A (ja) 2023-07-07
JPWO2021245223A5 JPWO2021245223A5 (https=) 2024-06-03
JP2023529095A5 JP2023529095A5 (https=) 2024-06-03

Family

ID=71016459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573504A Pending JP2023529095A (ja) 2020-06-05 2021-06-04 高用量低体積のボツリヌス毒素による顔のシワの治療

Country Status (13)

Country Link
US (1) US12599550B2 (https=)
EP (2) EP4161562B1 (https=)
JP (1) JP2023529095A (https=)
KR (1) KR20230020961A (https=)
CN (1) CN115666629A (https=)
AU (1) AU2021286196A1 (https=)
BR (1) BR112022023413A2 (https=)
CA (1) CA3177835A1 (https=)
ES (1) ES3013130T3 (https=)
IL (1) IL298399A (https=)
MX (1) MX2022014564A (https=)
TW (1) TW202214211A (https=)
WO (1) WO2021245223A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
KR20240169045A (ko) * 2022-04-01 2024-12-02 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 보툴리눔 독소 단백질 조성물, 이의 제조 방법 및 용도
EP4626556A1 (en) * 2022-11-28 2025-10-08 Merz Pharma GmbH & Co. KGaA High concentration botulinum toxin treatment for neck rejuvenation
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
HUE037509T2 (hu) * 2011-09-29 2018-09-28 Cellsnap Llc Készítmények és eljárások toxigenicitás meghatározására
PL3014267T3 (pl) * 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DERMATOLOGIC SURGERY, vol. 33(s1), JPN6025017172, 2007, pages 51 - 59, ISSN: 0005583778 *
J DRUGS DERMATOL., vol. 15(12), JPN6025041783, 2016, pages 1544 - 1549, ISSN: 0005707389 *
JOURNAL OF COSMETIC DERMATOLOGY, vol. 6, JPN6025041781, 2007, pages 152 - 158, ISSN: 0005707388 *

Also Published As

Publication number Publication date
CN115666629A (zh) 2023-01-31
EP4161562A1 (en) 2023-04-12
MX2022014564A (es) 2022-12-15
EP4467202A3 (en) 2025-02-19
WO2021245223A1 (en) 2021-12-09
EP4161562B1 (en) 2024-11-20
AU2021286196A1 (en) 2022-12-01
KR20230020961A (ko) 2023-02-13
EP4467202A2 (en) 2024-11-27
ES3013130T3 (en) 2025-04-11
TW202214211A (zh) 2022-04-16
BR112022023413A2 (pt) 2022-12-20
IL298399A (en) 2023-01-01
CA3177835A1 (en) 2021-12-09
US20230329996A1 (en) 2023-10-19
US12599550B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
US12144847B2 (en) Non-protein clostridial toxin compositions
JP2023529095A (ja) 高用量低体積のボツリヌス毒素による顔のシワの治療
JP6140445B2 (ja) 血管の過敏反応と関連した皮膚状態を治療する方法および組成物
US20230158129A1 (en) Clostridial toxin - hyaluronic acid compositions
JP2015514074A (ja) 局所化学的神経麻痺薬を使用して皺を処置する方法
TW202435908A (zh) 組成物及應用其之注射裝置
JP2011157331A (ja) 高用量投与が可能なボツリヌス毒素製剤
RU2835617C1 (ru) Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина
KR20230071072A (ko) 보툴리눔 독소 조성물
HK40085901A (en) High dose and low volume botulinum toxin treatment of facial wrinkles
KR20250113350A (ko) 비-복합체 보툴리눔 독소 조성물의 빠른 효력 발현 효과 및 이와 관련된 방법
KR20250113431A (ko) 목을 재생하기 위한 고 농도 보툴리눔 독소 치료
HK40122667A (zh) 颈阔肌中注射肉毒杆菌毒素用於下面部和颈部年轻化

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260212